Clinical Trial Update: Open Label Study Investigating Safety and Efficacy of NPL2009 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance Tasks, Adults With Fragile X Syndrome [Phase 1, Phase 2]

View source ↗

Summary

An open-label Phase 1/2 study evaluated the safety and potential efficacy of NPL2009 at 50-150 mg in adults with Fragile X Syndrome. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fragile Syndrome

Drugs mentioned

• NPL2009

Snippet

Sponsor: Neuropharm | Conditions: Fragile X Syndrome | Phase 1, Phase 2 | Status: COMPLETED